Articles |

Synergetic Effect of Interleukin-4 and Transforming Growth Factor-β1 on Type I Collagen Gel Contraction and Degradation by HFL-1 Cells*: Implication in Tissue Remodeling FREE TO VIEW

Xiangde Liu, MD; Heather Conner, BS; Tetsu Kobayashi, MD, PhD; Shinji Abe, MD, PhD; Qiuhong Fang, MD; Fu-Qiang Wen, MD, PhD; Stephen I. Rennard, MD, FCCP
Author and Funding Information

*From the University of Nebraska Medical Center, Omaha, NE.

Correspondence to: Xiangde Liu, MD, Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, 985125 Nebraska Medical Center, Omaha, NE 68198-5125; e-mail: xdliu@unmc.edu

Chest. 2003;123(3_suppl):427S-428S. doi:10.1378/chest.123.3_suppl.427S
Text Size: A A A
Published online

Interleukin (IL)-4 and transforming growth factor (TGF)-β1 have been implicated in the pathogenesis of asthma and fibrosis, respectively. We hypothesized that IL-4 and TGF-β1 have a synergetic effect in the formation of subepithelial or peribronchial fibrosis in asthma following chronic inflammation. To demonstrate this, human fetal lung fibroblasts were cultured in native type I collagen gels. Both contraction in the presence or absence of IL-4 and/or TGF-β1, and the effect of IL-4 and/or TGF-β1 on native type I collagen degradation, induced by IL-1β and tumor necrosis factor (TNF)-α plus trypsin, was determined. Both IL-4 (1 to 10 ng/mL) and TGF-β1 (10 to 100 pmol/L) were able to augment collagen gel contraction in a concentration-dependent manner. TGF-β1 effect was more potent than IL-4 within 48 h after release of the gels (TGF-β, 57.48 ± 1.40% and IL-4, 70.26 ± 0.32%, respectively, vs 76.95 ± 0.99% of control on day 1). After 2 days, however, the potency of TGF-β1 was dramatically decreased, while the IL-4 effect was more potent after 3 days (TGF-β1, 50.50 ± 0.11% and IL-4, 26.97 ± 0.38% vs 46 ± 1.54% of control on day 5). When IL-4 and TGF-β1 were added together, further augmentation was observed at all times (47.31 ± 0.88% on day 1 and 22.89 ± 0.85% on day 5). In addition, IL-4 and/or TGF-β1 significantly inhibited collagen gel degradation induced by IL-1β and TNF-α plus trypsin (hydroxyproline in the remaining gels: IL-1β plus TNF-α, 21.0 ± 1.3; IL-1β plus TNF-α plus IL-4, 35.3 ± 1.4; IL-1β plus TNF-α plus TGF-β1, 55.6 ± 1.7; IL-1β plus TNF-α plus IL-4 plus TGF-β1, 69.6 ± 1.8 vs 97.3 ± 2.9 μg per gel of control). Consistently, IL-4 and/or TGF-β1 stimulated tissue inhibitor of metalloproteinase-1 production (control, 180.8 ± 6.44; IL-4, 316.1 ± 19.79; TGF-β1, 550.2 ± 15.6; IL-4 plus TGF-β1, 865.3 ± 25.3 ng/mL). Furthermore, IL-4 and/or TGF-β1 had no effect on matrix metalloproteinase (MMP)-1 production but significantly blocked the trypsin-mediated conversion of pro–MMP-1 into an active form of MMP-1. These data suggest that IL-4 and TGF-β1 have a collaborative effect in augmenting fibroblast-mediated extracellular matrix contraction and can inhibit extracellular matrix degradation mediated by metalloproteinases. Thus, IL-4 and TGF-β1 may play an important role in fibroblast-mediated tissue remodeling and fibrosis.

Abbreviations: IL = interleukin; MMP = matrix metalloproteinase; TGF = transforming growth factor; TNF = tumor necrosis factor




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543